In 12 out of 14 patients with detected EGFR mutation and three out of four patients with detected ALK fusion that were classified as stage IV lung cancer disease after diagnosis, has the analysis of treatment predictive biomarkers led to antitumoral treatment with tyrosine kinase inhibitor in the first-line setting. This evidence concerns the gene ALK and lung cancer.